<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481143</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670ADE03</org_study_id>
    <nct_id>NCT00481143</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload</brief_title>
  <official_title>A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 in Patients Diagnosed With Low and INT-1 Risk Myelodysplastic Syndrome (MDS) and Transfusion-dependent Iron Overload</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of iron chelation using deferasirox
      in low and INT-1 risk (referring to the international prognostic scoring system, IPSS) MDS
      patients who show signs of iron overload due to repeated blood transfusions.

      This trial is not recruiting patients in the United States.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess iron chelation by comparing serum ferritin values at baseline vs. 52 weeks of treatment with deferasirox</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of deferasirox assessed by monitoring and recording all adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Transfusion Dependent Iron Overload</condition>
  <arm_group>
    <arm_group_label>deferasirox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICL670/Deferasirox</intervention_name>
    <arm_group_label>deferasirox</arm_group_label>
    <other_name>ICL670</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MDS patients presenting with low or intermediate-1 IPSS risk and transfusional iron
             overload

          -  Patients of either gender and age ≥ 18 years

          -  History of at least 20 units of red blood cell transfusions or 100mL/kg of prepacked
             red blood cells (PRBCs)

          -  Patients can be either naïve to iron chelation or have had prior treatment with
             deferoxamine (DFO) or deferiprone (L1)

          -  Females of childbearing potential must use double-barrier contraception, oral
             contraceptive plus barrier contraceptive, or must have undergone clinically documented
             total hysterectomy and/or oophorectomy, tubal ligation or be postmenopausal defined by
             amenorrhea for at least 12 months.

        Exclusion Criteria:

          -  Non-transfusion related iron overload

          -  Treatment with deferasirox (ICL670) before study start

          -  Patients with a concomitant malignant disease

          -  Patients with out of range lab values

          -  History of nephrotic syndrome

          -  Patients with a previous history of clinically relevant ocular toxicity related to
             iron chelation

          -  Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the
             patient from undergoing study treatment

          -  Patients treated with systemic investigational drugs within the past 4 weeks or
             topical investigational drug within the past 7 days

          -  Any other surgical or medical condition which might significantly alter the
             absorption, distribution, metabolism or excretion of any drug.

          -  Patients with active uncontrolled infectious disease

          -  Pregnancy or breast feeding

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmeceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=4784</url>
    <description>Clinical Trial Results for CICL670ADE03 at Novartis Clinical Trials.com</description>
  </link>
  <results_reference>
    <citation>Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.</citation>
    <PMID>23073603</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2007</study_first_submitted>
  <study_first_submitted_qc>May 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2007</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>iron overload</keyword>
  <keyword>chelation</keyword>
  <keyword>chelators</keyword>
  <keyword>ICL670</keyword>
  <keyword>Deferasirox</keyword>
  <keyword>serum ferritin</keyword>
  <keyword>LIC</keyword>
  <keyword>transfusional hemosiderosis</keyword>
  <keyword>Refractory Anemia</keyword>
  <keyword>RA</keyword>
  <keyword>Refractory Anemia with Ringed Sideroblasts</keyword>
  <keyword>RARS</keyword>
  <keyword>blood transfusions</keyword>
  <keyword>Mydelodysplastic Syndrome(s)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

